Clinical Usefulness of Arbekacin

Clinical Usefulness of Arbekacin

Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. Here, we reviewed...

Full description

Bibliographic Details
Main Authors: Lee, Jae Hoon, Lee, Chang-Seop
Format: Online
Language:English
Published: The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835429/
id pubmed-4835429
recordtype oai_dc
spelling pubmed-48354292016-04-21 Clinical Usefulness of Arbekacin Lee, Jae Hoon Lee, Chang-Seop Review Article Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. Here, we reviewed in vitro data on arbekacin in Staphylococci and Gram-negative microorganisms. We also reviewed clinical studies for clinical efficacy and microbiologic efficacy data in patients with identified MRSA and suspected MRSA infections. The overall clinical efficacy ranged from 66.7% to 89.7%. The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to other glycopeptides with respect to clinical and microbiological efficacy rates. Combination trials with other antibiotics suggest that arbekacin will be a promising strategy to control Enterococcus spp. multi-drug resistant P. aeruginosa. The major adverse reaction was nephrotoxicity/hepatotoxicity, but patients recovered from most adverse reactions without any severe complications. Based on these results, arbekacin could be a good alternative to vancomycin/teicoplanin in MRSA treatment. Finally, therapeutic drug monitoring is recommended to maximize clinical efficacy and decrease nephrotoxicity. The Korean Society of Infectious Diseases and Korean Society for Chemotherapy 2016-03 2016-03-31 /pmc/articles/PMC4835429/ /pubmed/27104010 http://dx.doi.org/10.3947/ic.2016.48.1.1 Text en Copyright © 2016 by The Korean Society of Infectious Diseases and Korean Society for Chemotherapy http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Lee, Jae Hoon
Lee, Chang-Seop
spellingShingle Lee, Jae Hoon
Lee, Chang-Seop
Clinical Usefulness of Arbekacin
author_facet Lee, Jae Hoon
Lee, Chang-Seop
author_sort Lee, Jae Hoon
title Clinical Usefulness of Arbekacin
title_short Clinical Usefulness of Arbekacin
title_full Clinical Usefulness of Arbekacin
title_fullStr Clinical Usefulness of Arbekacin
title_full_unstemmed Clinical Usefulness of Arbekacin
title_sort clinical usefulness of arbekacin
description Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin has antibacterial activities against high-level gentamicin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii et al. Here, we reviewed in vitro data on arbekacin in Staphylococci and Gram-negative microorganisms. We also reviewed clinical studies for clinical efficacy and microbiologic efficacy data in patients with identified MRSA and suspected MRSA infections. The overall clinical efficacy ranged from 66.7% to 89.7%. The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to other glycopeptides with respect to clinical and microbiological efficacy rates. Combination trials with other antibiotics suggest that arbekacin will be a promising strategy to control Enterococcus spp. multi-drug resistant P. aeruginosa. The major adverse reaction was nephrotoxicity/hepatotoxicity, but patients recovered from most adverse reactions without any severe complications. Based on these results, arbekacin could be a good alternative to vancomycin/teicoplanin in MRSA treatment. Finally, therapeutic drug monitoring is recommended to maximize clinical efficacy and decrease nephrotoxicity.
publisher The Korean Society of Infectious Diseases and Korean Society for Chemotherapy
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835429/
_version_ 1613567564657459200

Similar Items